Claims for Patent: 8,790,896

Summary for Patent: 8,790,896

Title:	Method for increasing protein expression in cells
Abstract:	The present invention relates to a method for increasing the expression of a protein in cells, preferably in eukaryotic cells, by reducing the number of RNase L cleavage sites in the coding and/or non-coding region of the nucleic acid sequence of said protein. Furthermore, it relates to nucleic acid sequences exhibiting a reduced number of RNase L cleavage sites as well as to the proteins translated from such sequences.
Inventor(s):	Khabar; Khalid S. (Riyadh, SA)
Assignee:	King Faisal Specialist Hospital & Research Centre (Riyadh, SA) Terramark Markencreation GmbH (Bremen, DE)
Application Number:	13/144,621
Patent Claims:	1. A method for increasing the expression of a protein in a cell, said method comprising the step of reducing the number of RNase L cleavage sites in a nucleic acid sequence encoding said protein, and wherein the cell is a eukaryotic cell. 2. The method according to claim 1, wherein the number of RNase L cleavage sites is reduced by at least 10%. 3. The method according to claim 1, wherein said cleavage sites are UU and/or UA dinucleotides. 4. The method according to claim 1, wherein the step of reducing the number of RNase L cleavage sites reduces the number of said sites in a coding region of said nucleic acid sequence. 5. The method according to claim 4, wherein the step of reducing the number of RNase L cleavage sites in said nucleic acid sequence is performed without altering the amino acid sequence of said protein. 6. The method according to claim 5, wherein in the step of reducing the number of RNase L cleavage sites a codon comprising a UU and/or UA dinucleotide is exchanged for an alternative codon not comprising a UU and/or UA dinucleotide and coding for the same amino acid. 7. The method according to claim 5, wherein in the step of reducing the number of RNase L cleavage sites at least one codon of an adjacent pair of codons comprising a UU and/or UA dinucleotide is exchanged for an alternative codon coding for the same amino acid so that said adjacent pair of codons no longer comprises a UU and/or UA dinucleotide. 8. The method according to claim 6, wherein said alternative codon is a more frequently used codon in said cell. 9. The method according to claim 1, wherein the step of reducing the number of RNase L cleavage sites reduces said number in a non-coding region of said nucleic acid sequence. 10. The method according to claim 9, wherein said non-coding region is a 5'UTR, a 3'UTR, or an intron. 11. The method according to claim 9, wherein the step of reducing the number of RNase L cleavage sites is performed by mutation, deletion, or insertion of one or more nucleotides. 12. The method according to claim 1, further comprising the step of codon optimization prior to the step of reducing the number of RNase L cleavage sites. 13. The method according to claim 1, further comprising the step of transfecting said nucleic acid sequence encoding said protein into said cell in an expression active PCR product or contained in an expression vector after the step of reducing the number of RNase L cleavage sites. 14. The method according to claim 13, further comprising the step of translating said protein from said expression active PCR product or expression vector in said cell. 15. The method according to claim 1, wherein said protein is selected from the group consisting of reporter proteins, therapeutic proteins, antibodies, vaccines, membrane proteins, fusion proteins, blood plasma proteins, cytokines, interferons, growth factors, chemokines, and GPCRs.

Details for Patent 8,790,896

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2029-01-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2029-01-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2029-01-19